The generation of an in vitro major histocompatibility complex class I specific response of CD4 -CD8 -T cell receptor (TCR) ctO cytotoxic T lymphocytes (CTL) and their allogeneic tumor rejection were investigated . Inocula ofBALBRLo' 1 were rejected in C57BL/6 (B6) mice treated with minimum essential medium (MEM) (control), anti-L3T4 (CD4) monoclonal antibody (mAb) or anti-Lyt-2.2 (CD8) mAb and CTL against the tumor were generated in vitro. No rejection and no induction of CTL were observed in B6 mice treated with anti-L3T4 (CD4) plus anti-Lyt-2 .2 (CD8) mAb. CTL with the classical Thy-1+CD3+CD4 -CD8+ TCR aß phenotype were generated in mixed lymphocyte tumor cell culture (MLTC) spleen cells from B6 mice treated with MEM (control) or anti-L3T4 (CD4) mAb, whereas CTL with an unusual Thy-1+CD3+CD4 -CD8 -TCR aß phenotype were generated in MLTC spleen cells from anti-Lyt-2 .2 (CD8) mAb-treated B6 mice. Both types of CTL were reactive with both H-2Kd and Dd (Ld) class I antigen . These findings suggest that when CD4+ cells were blocked by anti-L3T4 (CD4) mAb, CD8+ CTL mediated rejection, and when CD8+ cells were blocked by anti-Lyt-2.2 (CD8) mAb, CD4+ cells were capable of mediating rejection, although less efficiently than CD8+ cells, by inducing CD4 -CD8 -TCR aß CTL. The finding that adoptive transfer of CD4 and CD8-depleted MLTC spleen cells, obtained from anti-Lyt-2.2 (CD8) mAbtreated B6 mice that had rejected BALBRLa 1, resulted in rejection of BALBRLa 1 inoculated into B6 nu/nu mice confirmed the above notion . CTL clones with the CD4 -CD8 -TCR aß phenotype specific for Ld were established .
T hymocytes with the CD4 -CD8 -phenotype constitute about 5% of all cells in the thymus of adult mice (1) . The TCR cxß-bearing subset constitutes 2-30% of the CD4 -CD8 -thymocytes in different mouse strains and displays a CD3+, HSA -, CD5h'gh, IL2R-, Pgp-1+, B220 -, and Qa-2+ phenotype (2) (3) (4) (5) (6) . Although these cells appear to have a functional TCR (7), the origin and developmental pathway of CD4 -CD8 -TCR aß cells is currently unknown. Recently, however, it was shown that tolerance-related Vß clonal deletion took place in CD4 -CD8 -TCR aß thymocytes from mice with Mls' and Mlsr alleles and mice expressing I-E (8). Clonal deletion has been shown to occur at the stage of CD4+CD8+ thymocytes and to involve the CD4 or CD8 molecule (9) (10) (11) . These findings suggest that CD4 -CD8' TCR aß thymocytes are formed at a late stage of differentiation by down-regulation of ecules (1, 8) . Alternatively, these cells could represent an independent lineage of T cells that never express CD4 and CD8 molecules during their differentiation.
Although appreciable numbers of CD4 -CD8 -TCR aß cells are found in the thymus, these cells are rarely detected in peripheral lymphoid tissues. However, CD4 -CD8 -TCR aß cells have been shown to accumulate in the lymph nodes of autoimmune lpr (12-15) or gld (13, 16, 17) mice. The CD4 -CD8 -TCR a,ß cells in these mice also undergo Vß clonal deletion (8, 18 ) and thymectomy prevents disease development (19, 20) . These findings suggest that CD4 -CD8 -TCR aß cells in the lymph nodes of these mice are derived from thymocytes with this phenotype . Recently, T cells with this phenotype have been shown to be present in the lymph nodes of normal mice (21) .
In this paper, we report that a CD4 -CD8 -TCR aß CTL response specific for both H-2K' and Dd (Ld) class I antigen was generated in C57BL/6 (B6) 1 mice that had been treated with anti-Lyt-2 .2 (CD8) mAb and had rejected the BALBRLo 1 tumor, and that adoptive transfer of these cells to B6 nu/nu mice resulted in rejection of the tumor.
Materials and Methods
Mice. A/J, BALB/c, C57BL/6 (B6), B10.A, B10.D2 and C3H/He mice were purchased from Japan SLC Inc. (Shizuoka, Japan) . Breeding pairs of C3H.OH, B10.A (5R), B10.AQR and B10.HTG mice were provided by Dr. K. Moriwaki (National Institutes of Genetics, Mishima, Japan) . Breeding pairs of B6 nu/+ mice were provided by Dr. K. Kuribayashi (Faculty of Medicine, Kyoto University, Kyoto, Japan) . Breeding pairs of BALB.B mice were provided by Dr. H. Fujiwara (Osaka University Medical School, Osaka, Japan) . These mice were bred in the Laboratory Animal Center for Biomedical Research (Nagasaki University School of Medicine, Nagasaki, Japan) .
Tumor. BALBRLU 1 is a radiation-induced leukemia (22) . B6LK is a nitrosomethylurea-induced thymic leukemia that expresses TCR a/3, CD4, and CD8 on the cell surface. K4D11 is a T cell lymphoma that developed in a C3H TgTla'-3-1 transgenic mouse and expresses TCR -yb, but not CD4 or CD8, on the cell surface (23) . The tumors were maintained in the strain of origin .
Antibodies. Anti-L3T4 (CD4) mAb, a rat antibody of the IgG2b immunoglobulin class, produced by hybridoma GK1.5 (24) , was provided by Dr. F. Fitch (University of Chicago, Chicago, IL). Anti-Lyt-2 .2 (CD8) mAb, a mouse antibody of the IgG2a class, produced by hybridoma 19/178 (25) was provided by Dr. U. Hammerling (Memorial Sloan-Kettering Cancer Center, New York, NY). Anti-TCR a mAb, a hamster antibody of the IgG class, produced by hybridoma H57-597 (26) , was provided by Dr . R. Kubo (NationalJewish Center, Denver, Co.) . Anti-TCR S mAb, a hamster antibody of the IgG class, produced by hybridoma 3A10 (27) was provided by Dr. S. Itohara (M .IT, Cambridge, MA). Anti-CD3 mAb, a hamster antibody of the IgG class, produced by hybridoma 145-2C11(28), was provided by Dr. J.A . Bluestone (University of Chicago, Chicago, IL). Anti-thymus leukemia (TL) mAb's were rat antibodies of the IgG2a and IgG2b classes produced by hybridoma 168 and 177, respectively (29) . Anti-Qa 2 mAb is a mouse IgM antibody produced by a hybridoma HDQa-2 . Anti-Qa 3 mAb is a mouse IgG2a antibody produced by a hybridoma Qa3-59 . Anti-H-2Kd mAb is a mouse IgG2a antibody produced by a hybridoma HB159. Anti-H-2D' mAb is a mouse IgG2a antibody produced by a hybridoma HB102 (30) . Both these mAbs were obtained from the American Type Culture Collection (Rockville, MD). Anti-H-2Ld mAb is a mouse IgG2a antibody produced by a hybridoma 30-5-7 (31) . H-2d antibodies used are B6 anti-BALBRLa 1, B6 anti-BALB/c methylcholanthrene sarcoma Meth A (BALBMeth A) and B6 anti-BALB/c spleen cells.
Cytofluorometric Analysis. Cells (1-2 x 106) were incubated with mAb for 30 min at 4°C. The following mAb's were used : PE-conjugated anti-L3T4 (CD4) mAb (clone GK1.5), FITCconjugated anti-Lyt-2 (CD8) mAb (clone 53-6 .7), and FITCconjugated antiThy-1.2 mAb (clone 30-1112) were obtained from Becton Dickinson & Co. (Mountain View, CA) . Biotin-conjugated 1 Abbreviations used in this paper: B6, C57BL/6; bml, B6 .C-H-2bmi; bm12, B6 .C-H-2bm1z ; MGS, mean graft survival; MLTC, mixed lymphocyte tumor cell culture ; MMC, mitomycin C; TL, thymus leukemia .
194
CD4 -CD8 -T Cell Receptor tx(3 Cytotoxic T Lymphocyte In Vitro Sensitization of Spleen Cells. Mixed lymphocyte tumor cell culture (MLTC) was performed by incubating responder spleen cells (5 x 10') with 5 x 106 mitomycin C (MMC)-treated BALBRLo' 1 cells. MMC treatment was done by incubating cells with MMC at a concentration of 100,ug/ml for 30 min at 37°C . The culture medium was RPMI 1640 supplemented with 10% heatinactivated FCS, 2 mM glutamine, 100 U of penicillin per ml, 100 ,ug of streptomycin per ml, and 50 AM 2-ME . MLTC cells were harvested after 5 or 6 d culture and used as effector cells in assays of cell-mediated cytotoxicity.
Pretreatment ofEffector Cells with MAband Complement (C). Aliquots of MLTC cells (5 x 106) or cloned CTL (2 x 10 6) were incubated with mAb (diluted 1:20 with MEM) in a volume of 0.2 ml for 30 min at 4°C. The cells were then washed once and resuspended in 0.75 ml of preselected rabbit serum (diluted 1:10 with MEM) as a source of C. After incubation for 30 min at 37°C, the cells were washed three times before use.
Cell-mediated Cytotoxicity Assay. BALBRLO' 1 or Con A blasts were labeled with "Cr by incubating 5 x 10 6 cells with 2 MBq of Na2CrO 4 (New England Nuclear, Boston, MA) in 0.3 ml of medium for 45 min at 37°C in an atmosphere of 5% CO2 in air. Then the cells were washed twice with culture medium and used as target cells. In direct assays, 2 x 104 labeled target cells (100 jl) were incubated with the effector cell suspension (100 JAI) . In antibody blocking assays, serially diluted mAb or antiserum (50 P,1) was added to the culture of effector (50 IAl) and labeled RLu 1 target cells (2 x 10 4) (50 1A1) during assay. After incubation for 3 h at 37°C, the supernatants (100 Etl) were removed and their radioactivity was measured in an Aloka ARC 300 y counter. The percentage of specific lysis was calculated by the following equation : (a-b/c-b) x 100, where a is the radioactivity in the supernatant of target cells mixed with effector cells, b is that in the supernatant of target cells incubated alone, and c is that in the supernatant after lysis of target cells with NP-40.
Establishment and Maintenance of Cytotoxic T Lymphocyte Clones. Limited numbers of MLTC cells were cultured with 5 x 105 irradiated (2,000 tad) syngeneic spleen cells and 5 x 103 irradiated (10,000 tad) tumor cells in a volume of 0.2 ml in 96-well flatbottomed microplates (Corning 25860; Corning Glass Works, Corning, NY). After culture for 14 d, cell growth was assessed microscopically and cytotoxicity was measured using half the culture (0 .1 ml). Cells in wells that showed cytotoxicity were transferred to 24-well culture plates (Corning 25820; Corning Glass Works) and maintained by culture with 5 x 106 irradiated (2,000 tad) syngeneic spleen cells and 5 x 10 4 irradiated (10,000 tad) tumor cells in medium containing human recombinant IIr2 (Takeda Pharmaceutical, Osaka, Japan) at a concentration of 0.1 U/ml . After initial expansion, CTL were recloned and passaged every 5 d by transferring 105 cells to new wells of multiwell plates .
Tumor Assay. BALBRLo' 1 cells were harvested in MEM medium and washed twice. The hair of the back of mice was shaved with animal clippers and the tumor cells (2 x 106) were injected i.d . through a 27-gauge needle . Tumor diameters at right angles were measured with vernier calipers to calculate the mean diameter.
Antibody Administration . Mice were anesthetized with ether and 200 I1 of antibodies (ascites diluted 1:8 with MEM) was injected through the retrobulbar venous plexus .
We found previously by antibody-mediated complementdependent cytotoxicity assay that injections of anti-L3T4 (CD4) mAb and anti-Lyt-2.2 (CD8) mAb resulted in the elimination from the peripheral lymphoid tissues of CD4 * cells and CD8' cells, respectively (34) Adoptive Transfer. Either CD4, or CD4 and CD8-depleted MLTC cells (6 x 106) were adoptively transferred to B6 nu/nu mice 5 d before challenge of the mice with BALBRL0' I tumor cells. To ensure depletion of CD4* cells, and of CD4' and CD8* cells, the mice were treated with anti-L3T4 (CD4) mAb, and both anti-L3T4 (CD4) and anti-Lyt-2.2 (CD8) mAb, respectively, during tumor assay.
Northern Blot Analysis. Total RNA's from MLTC cells, cell lines, and tumor cells were isolated by the guanidine thiocyanate/CsCl procedure (35) . Fractionated RNA was blotted onto nitrocellulose filters (Schleicher & Schuell, Keene, NH) and hybridized with ["P]dCTP-labeled probes in the presence of 50% formamide for 18 h at 45*C as described (36) . Filters were washed and exposed to X-ray film (XAR-5 ; Eastman Kodak, Rochester, NY). The following probes were used : pSP64L3T4 for L3T4 (CD4) ( 
In Vitro Cytotoxic T Lymphocyte Responses of Spleen Cells from MEM (Control), Anti-L3T4 (CD4)MA 4 or Anti-Lyt-2.2 (CD8) MAb-Treated B6 Mice that Rejected BALBRLa 1. CTL were generated by in vitro stimulation with mitomycin C (MMC)-treated BALBRLO' 1 cells of spleen cells from B6 mice treated with MEM (control), anti-L3T4 (CD4) mAb or anti-Lyt-2.2 (CD8) mAb that had rejected the BALBRLO' 1 tumor, but not on similar treatment of spleen cells from B6 mice treated with both mAbs and bearing BALBRLO' 1 tumor (9-13 mm diameter) obtained 12 d aftei tumor inoculation (Fig . 2) . The cytotoxicity generated in MLTC spleen cells from B6 mice treated with MEM (control) or anti-L3T4 (CD4) mAb was abolished by treatment with antiThy-1.2 mAb or anti-Lyt-2.2 (CD8) mAb, but not with anti-L3T4 (CD4) mAb and complement (C). On the other hand, the cytotoxicity generated in MLTC spleen cells from anti-Lyt-2.2 (CD8) mAb-treated B6 mice was abolished by treatment with antiThy-1.2 mAb, but not with anti-L3T4 (CD4) mAb or anti-Lyt-2 .2 (CD8) mAb and C.
Specificity Analysis and Antibody Blocking of CTL. The CD4 -CD8+ CTL generated in MLTC spleen cells from MEM (control) or anti-L3T4 (CD4) mAb-treated B6 mice that had rejected BALBRLO' 1 and the CD4 -CD8 -CTL generated in MLTC spleen cells from anti-Lyt-2.2 (CD8) mAbtreated B6 mice that had rejected BALBRLO' 1 showed similar specificities : these CTL lysed target cells that expressed either H-2Kd or H-2Dd (Ld) antigen (Fig. 3) . Next we examined the blocking of CTL with antibody. CD4 -CD8+ CTL were blocked by anti-CD3 mAb, anti TCR a mAb, anti-Lyt-2 .2 (CD8) mAb or anti-H-2d serum, but not by anti-L3T4 (CD4) mAb, as shown by additions of these antibodies to cultures during assays (Fig . 4 A) . On the other hand, CD4 -CD8-CTL were blocked by anti-CD3 mAb, antiTCR a mAb or anti-H-2d serum, but not by anti-L3T4 (CD4) mAb or anti-Lyt-2 .2 (CD8) mAb (Fig . 4 B) . Anti-H-2d serum used in these experiments include B6 anti-BALBRLO' 1, B6 anti-BALBMeth A and B6 anti-BALB/c spleen cells and.the effect was essentially similar. No blocking of either type of CTL was observed with the anti TL mAb, anti-Qa-2 mAb, or anti-Qa-3 mAb.
Cytofluorometric Analysis. Cytofluorometric analysis showed that in vivo administration of anti-L3T4 (CD4) mAb and anti-Lyt-2 .2 (CD8) mAb resulted in depletion of CD4+ and CD8+ cells, respectively, in peripheral lymphoid tissues. Depletion of CD4+ cells in spleen and lymph node cells was shown by a lack of cells that stained with PE anti-L3T4 (CD4) mAb, and by a lack of Thy-1+ cells that would double label with either FITC anti-rat Ig or anti-L3T4 (CD4) mAb plus FITC anti-rat Ig . Similarly, depletion of CD8+ cells was evident by a lack of cells that stained with FITC rat anti-Lyt-2 (CD8) mAb, and by a lack of Thy-1 + cells that would double label with either FITC anti-mouse Ig or anti-Lyt-2.2 (CD8) mAb plus FITC anti-mouse Ig .
The populations of CD4+ and CD8+ cells in 6-d cultures of MLTC spleen cells from MEM (control)-treated B6 mice that had rejected BALBRLO' 1 were approximately 20 and 70%, respectively, of the total cells (Fig. 5 A) . Scarcely any CD4+ or CD8+ cells were detected in cultures of MLTC spleen cells from B6 mice treated with anti-L3T4 (CD4) mAb or anti-Lyt-2 .2 (CD8) mAb that had rejected BALBRLO' 1 (Fig. 5, B and C) . Since the cytotoxicity generated in MLTC spleen cells from anti-Lyt-2 .2 (CD8) mAb-treated B6 mice that had rejected BALBRLO' 1 resided mainly in cells with the unusual Thy-1+ CD4-CD8 -phenotype, as described above, TCR expression in this cell population was examined . MLTC spleen cells from anti-Lyt-2 .2 (CD8) mAb-treated B6 mice were depleted of both CD4+ and CD8+ cells by mAb and C (Fig. 5 D) . Thy-1+ CD3+ cells constituted about 70-80% of the total CD4 -CD8 -cells in MLTC (Fig. 5 E) , and most of these were TCR aß-positive cells (Fig. 5 F) . TCR Vß6-and Vß8-positive cells constituted -0% and x+20% of the Thy-1 positive cells, respectively (Fig. 5, G  and H) .
Rejection of BALBRLOF 1 Inoculated into B6 nu/nu Mice by Adoptive Transfer of CD4 -CD8 -Cells Obtained from AntiLyt-2.2 (CD8) MAb-Treated B6 Mice that Had Rejected BALBRLo' 1 . MLTC spleen cells from anti-L3T4 (CD4) mAb-treated B6 mice that had rejected BALBRLU 1 were treated with anti-L3T4 (CD4) mAb and C, and 6 x 106 cells were adoptively transferred to B6 nu/nu mice 5 d before challenge of the mice with BALBRLO' 1 tumor. In these mice, BALBRLU 1 grew to a tumor, and then regressed (Fig. 6 A) . For examination of the in vivo effector activity of Thy-1+ CD4 -CD8 -CTL, MLTC spleen cells from anti-Lyt-2 .2 (CD8) mAb-treated B6 mice that had rejected BALBRLO' 1 were treated with both anti-L3T4 (CD4) mAb and anti-Lyt-2 .2 (CD8) mAb and C, and the same number of cells were similarly transferred to B6 nu/nu mice. To re- 197 Mieno et al . duce the possibility of involvement of CD4+ and CD8+ cells that escaped from depletion and proliferated, we added both anti-L3T4 (CD4) mAb and anti-Lyt-2.2 (CD8) mAb during tumor assay. Adoptive transfer of CD4 -CDS -cells resulted in rejection of BALBRLO' 1 tumors, although less efficiently than adoptive transfer of a CD4 -CD8+ population (Fig. 6 C) . Administration of antiTCR 0 mAb (H57-597) abolished rejection by the CD4 -CD8 -population, confirming the TCR aR phenotype of the effector cells (Fig.  6 D) . Administration of anti-L3T4 (CD4) mAb and/or anti-Lyt-2 .2 (CD8) mAb, or antiTCR /3 mAb (H57-597) alone had no effect on BALBRLO" 1 tumor growth in B6 nulnu mice. Thy-1+ CD4 -CD8 -CTL were recovered from MLTC spleen cells of B6 nulnu mice that had rejected 198 CD4 -CD8 -T Cell Receptor a,8 Cytotoxic T Lymphocyte BALBRLoa 1 after adoptive transfer of a CD4 -CD8 -population (Fig. 7) . Establishment of CD4 -CD8 -TCR a(3 CTL Clones. MLTC spleen cells from anti-Lyt-2.2 (CD8) mAb-treated B6 mice that had rejected BALBRLO' 1 were treated with anti-L3T4 (CD4) mAb plus anti-Lyt-2 .2 (CD8) mAb and C. The residual cells were plated at 1 cell/well in 96-well plates and cultured with irradiated BALBRLa 1 and B6 spleen cells. In this way, CTL clones S 1 and 2 were obtained from individual mice. Both these clones were found to be Thy-1+CD4-CD8 -TCRa#+Vs6 -VO8 -by cytofluorometry and were specific for Ld (Fig. 8) .
Northern Blot Analysis. The expression of L3T4 (CD4), Lyt-2 (CD8) and TCR genes in the MLTC spleen cells and the CTL clones S 1 and 2 were analyzed by Northern blotting. Transcripts of the L3T4 (CD4) and Lyt-2 (CD8) genes were detected in MLTC spleen cells from MEM-treated B6 mice that had rejected RLO' 1, but no transcripts of the Lyt-2 (CD8) gene were detected in MLTC spleen cells from anti-Lyt-2.2 (CD8) mAb-treated B6 mice that had rejected BALBRLO' 1 ( Fig. 9) . Transcripts of the TCR a, a, and y genes, but not of the TCR S, L3T4 (CD4) or Lyt-2 (CD8) genes, were detected in both S1 and 2 clones .
Discussion
In the present study, we demonstrated that MHC class I specific CD4 -CD8 -TCR ao CTL were generated in MLTC spleen cells from anti-Lyt-2.2 (CD8) mAb-treated B6 mice obtained after rejection of allogeneic BALBRLo°1. CD4 -CD8 -CTL were involved in mediating rejection of the tumor in these mice.
Inocula of BALBRLO' 1 were rejected in B6 mice treated with MEM (control), anti-L3T4 (CD4) mAb or anti-Lyt-2.2 (CD8) mAb and CTL against the tumor were generated in vitro. No rejection and no induction of CTL were observed in B6 mice treated with both anti-L3T4 (CD4) mAb and anti-Lyt-2.2 (CD8) mAb. CTL with the classical Thy-1 + CD3 'CD4 -CD8 + phenotype was generated in MLTC spleen cells from B6 mice treated with MEM (control) or anti-L3T4 (CD4) mAb, whereas CTL with an unusual Thy-1+CD3+CD4 -CD8 -phenotype were generated in MLTC spleen cells from anti-Lyt-2.2 (CD8) mAb-treated B6 mice. The CD4 -CD8 -phenotype of CTL was shown by elimination and blocking of cytotoxicity. Pretreatment of MLTC cells with antiThy-1 mAb, but not anti-L3T4 (CD4) mAb or anti-Lyt-2 (CD8) mAb and C abolished the cytotoxicity. Addition of anti-CD3 mAb, but not anti-L3T4 (CD4) mAb or anti-Lyt-2.2 (CD8) mAb blocked the cytotoxicity in the absence of added C. No difference was observed in the specificities of bulk CTL with the CD4 -CD8+ and CD4 -CD8 -phenotypes : both were reactive with either H-2Kd or Dd (L'). These findings suggest that when CD4+ cells were blocked by anti-L3T4 (CD4) mAb, CD8+ CTL mediated rejection efficiently, and when CD8+ cells were blocked by anti-Lyt-2.2 (CD8) mAb, CD4+ cells were capable ofmediating rejection, although less efficiently than CD8+ cells, by inducing CD4 -CDS -CTL .
The CD4 -CD8 -CTL demonstrated in this study use TCR a(3 but not -yb . AntiTCR a mAb (H57-597) blocked the in vitro cytotoxicity of CD4 -CD8 -CTL and tumor rejection in anti-Lyt-2 .2 (CD8) mAb-treated B6 mice (data not shown) or B6 nu/nu mice after adoptive transfer of CD4 -CD8 -CTL . Cytofluorometric analysis revealed that Thy-1+ cells from anti-Lyt-2 .2 (CD8) mAb-treated B6 mice contained approximately 70-80% of CD4-and CD8-depleted MLTC cells and that most of the cells were TCR ao-positive. V06-and V08-positive cells constituted 'ti0% and -20% of the Thy-1+ cells, their levels being similar to those in normal B6 thymorytes (42) . The CTL clones S 1 and 2 with the Thy-1+CD3+CD4 -CD8' TCR ciO phenotype were established from these MLTC cells .
The thymus was found to contain less than 1% of T cells with the CD4 -CD8 -TCR oiO phenotype (1) . The finding that these cells respond to various stimuli and produce IL-2 (7) suggests that thymorytes with the CD4 -CD8 -TCR cig phenotype are mature. Furthermore, clonal deletion has been shown to occur in these cells (8, 18) . Although thymorytes with this phenotype have been defined, no counterpart has been detected in the peripheral lymphoid tissues of normal mice. However, Guidos et al . The DNA probes used were pSP64L3T4 for L3T4 (CD4), pLy2C-1 for Lyt-2 (CD8), pclca for TCR a, PL5 for TCR 0, p8/10-2,y1 .1 for TCR y, and RAD11C for TCR 6.
nisms of allograft or tumor rejection mediated by CD4+ cells are unknown (43, 44) . One possible mechanism could be CD4-dependent induction of CD4 -CD8 -TCR a/3 effector cells. In this regard, it is noteworthy that the accumulation of CD4 -CD8 -as cells observed in certain autoimmune mice has been shown to be dependent on CD4+ cells. Treatment of MRTrlpr/lpr mice with anti-L3T4 (CD4) mAb prevented accumulation of CD4 -CD8' TCR a)3 T cells and the development of autoimmune disease (45) . This finding suggests that CD4 -CD8' TCR cio cells that are normally present in these mice are somehow stimulated to proliferate by activation of CD4+ cells. The fact that CD4 -CD8 -cells in enlarged lymph nodes undergo clonal deletion suggests that these cells are derived from normal counterparts in the thymus (8, 18) . Class I specific CD4 -CD8' a/3 CTL clones have been generated from lymph node cells fromgld mice (46) . CD4 -CD8 -effector cells were less efficient than CD4 -CI18+ effector cells in mediating tumor rejection . Significant delay of BALBRLO" 1 tumor rejection was observed in anti-Lyt-2 .2 (CD8) mAb-treated B6 mice compared with that in MEM (control) or anti-L3T4 (CD4) mAb-treated B6 mice, and also in B6 nu/nu mice after adoptive transfer of CD4 and CD8-depleted MLTC spleen cells obtained from anti-Lyt-2 .2 (CD8) mAb-treated B6 mice that had rejected BALBRLO' 1 compared with that in mice after adoptive transfer of CD4-depleted MLTC spleen cells obtained from anti-L3T4 (CD4) mAb-treated B6 mice . The exact reason for the difference between the efficiencies of CD4 -CD8 -and CD4 -CD8+ cells is unknown. CD4 -CD8 -effector cells could be less efficient than CD4 -CD8+ effector cells. Alternatively, the difference could be due to a lower number of CD4 -CD8 -TCR aR CTL precursors.
